Firstly, it promotes the STAT3 signaling pathway and macrophage M2-type activation, which are linked to the inhibition of the tumor immune response; secondly, it lowers the expression of MHC II and CD80 to impact macrophage antigen-presenting ability and T cell activation [122]. Here, CD80 is linked to neoplasm.